SCIENTIFIC POSTER_Monica Asencio Duran_1


To report a case of bilateral macular serous retinal detachment after treatment with Pimasertib, a MEK inhibitor.

Patients and Methods:

A 76 y.o patient with N-ras mutated metastatic skin melanoma developed visual impairment and bilateral macular serous detachment on OCT and angiography 2 weeks after initiation of oral pimasertib. Pimasertib is a MEK-inhibitor (mitogen-activated extracellular signal-regulated kinase) employed in advanced solid tumors, refractory to standard therapy or for which no effective standard therapy is available.


Complete visual and tomographic recovery was achieved after discontinuation of therapy due to visual and systemic adverse events.


New strategies for advanced diseases are emerging and the ophthalmologist must be aware in order to maintain the best quality of life for these patients.